At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 202 enrolled
Drug / intervention
CyclASol Ophthalmic Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-center, Open-label, Single-arm Clinical Trial to Assess the Long-term Safety and Tolerability of Topical CyclASol® for the Treatment of Dry Eye Disease in Subjects Who Completed the Clinical Trial CYS-004
In Brief
A Phase 3 clinical trial evaluating CyclASol Ophthalmic Solution for Dry Eye Disease (DED). Completed, enrolled 202 participants across 14 sites.
Detailed Summary
The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease (DED)
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartJan 2021
Primary CompletionApr 2022
Study CompletionMay 2022
TodayJul 2026
First PostedAug 21, 2020
Enrollment StartJan 4, 2021
Primary CompletionApr 30, 2022
Study CompletionMay 23, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.9 years ago
Interventions
CyclASol Ophthalmic Solutiondrug
Cyclosporine A solution in vehicle